PCI Biotech Holding ASA Market Cap ($274.95K)
Market Cap & Net Worth: PCI Biotech Holding ASA (PCIB)
PCI Biotech Holding ASA market cap. PCI Biotech Holding ASA (OL:PCIB) has a market capitalization of $274.95K (Nkr2.61 Million) as of November 1, 2026. Listed on the OL stock exchange, this Norway-based company holds position #31280 globally and #275 in its home market, demonstrating a -53.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PCI Biotech Holding ASA's stock price Nkr0.07 by its total outstanding shares 37326390 (37.33 Million). Also see cash efficiency ratio of PCI Biotech Holding ASA for how efficiently the company converts equity into cash flow.
PCI Biotech Holding ASA Market Cap History (2015–2026)
PCI Biotech Holding ASA market cap history from 2015 to 2026. Data shows change from $10.91 Million to $274.95K (-32.19% CAGR). Check PCIB live share price for real-time trading data and today's change.
PCI Biotech Holding ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PCI Biotech Holding ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PCI Biotech Holding ASA annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.69x
PCI Biotech Holding ASA's market cap is 0.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $10.91 Million | $10.47 Million | -$31.92 Million | 1.04x | N/A |
| 2016 | $54.70 Million | $10.47 Million | -$32.18 Million | 5.22x | N/A |
| 2017 | $153.52 Million | $10.25 Million | -$42.84 Million | 14.98x | N/A |
| 2018 | $103.30 Million | $9.59 Million | -$34.78 Million | 10.78x | N/A |
| 2019 | $301.26 Million | $9.37 Million | -$88.75 Million | 32.15x | N/A |
| 2020 | $109.59 Million | $7.37 Million | -$72.24 Million | 14.87x | N/A |
| 2021 | $54.64 Million | $6.27 Million | -$88.48 Million | 8.71x | N/A |
| 2022 | $8.05 Million | $4.75 Million | -$55.09 Million | 1.70x | N/A |
| 2023 | $8.23 Million | $2.99 Million | -$20.32 Million | 2.75x | N/A |
| 2024 | $4.67 Million | $6.74 Million | -$16.42 Million | 0.69x | N/A |
Competitor Companies of PCIB by Market Capitalization
Companies near PCI Biotech Holding ASA in the global market cap rankings as of November 1, 2026. Also see PCIB total assets for a full breakdown of the balance sheet.
Key companies related to PCI Biotech Holding ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of PCI Biotech Holding ASA (2015–2026)
Market capitalization of PCI Biotech Holding ASA from 2015 to today. Between 2015 and today, PCI Biotech Holding ASA's market cap moved from $10.91 Million to $ 274.95K, with a yearly change of -32.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr274.95K | -71.54% |
| 2025 | Nkr966.24K | -79.29% |
| 2024 | Nkr4.67 Million | -43.29% |
| 2023 | Nkr8.23 Million | +2.20% |
| 2022 | Nkr8.05 Million | -85.26% |
| 2021 | Nkr54.64 Million | -50.14% |
| 2020 | Nkr109.59 Million | -63.62% |
| 2019 | Nkr301.26 Million | +191.63% |
| 2018 | Nkr103.30 Million | -32.71% |
| 2017 | Nkr153.52 Million | +180.67% |
| 2016 | Nkr54.70 Million | +401.38% |
| 2015 | Nkr10.91 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of PCI Biotech Holding ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $274.95K USD |
| MoneyControl | $274.95K USD |
| MarketWatch | $274.95K USD |
| marketcap.company | $274.95K USD |
| Reuters | $274.95K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PCI Biotech Holding ASA
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more